Literature DB >> 21947321

Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2.

Hajime Iida1, Mitsuhiro Suzuki, Ryo Goitsuka, Hikaru Ueno.   

Abstract

CD133 has been recognized as a specific cell surface marker for cancer stem cells in various tumors, although its biological functions and transcriptional regulation remain unclear. We found that the CD133 expression level was up-regulated in the lung cancer cell lines N417, H358, and A549, when these cell lines were cultured under hypoxic conditions. Among the five promoters (P1-P5) of human CD133 gene loci, P1 promoter was most strongly associated with hypoxia-induced promoter activity of CD133 gene expression. The P1 promoter possesses several cis-regulatory elements, including RUNT, GATA, ETS, OCT, SRY, and CREB-binding sites. A series of deletion and base substitution mutants of the P1 promoter revealed that OCT- and SRY-binding sites are important for hypoxia-induced promoter activity. The chromatin immunoprecipitation assay further confirmed the direct binding of Octamer biding trans-cription factor 3/4 (OCT4) and/or SRY-box containing gene 2 (SOX2) to the P1 promoter region of CD133 gene loci. In addition, the enhancement of both OCT4 and SOX2 expression by the α subunit of hypoxia-inducible factors (HIF1α and HIF2α) was required for hypoxia-induced CD133 expression. Knockdown of OCT4 or SOX2 expression in N417 cells with stabilized HIF1α and/or HIF2α abolished CD133P1 activity, while ectopic OCT4 or SOX2 expression triggers CD133P1 activity in the absence of HIF1α or HIF2α. Thus, in the hypoxic conditions, OCT4 and SOX2, both of which are induced by HIF1α/HIF2α. promote CD133 expression in the lung cancer cells via their direct interaction with the P1 promoter.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947321     DOI: 10.3892/ijo.2011.1207

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  50 in total

1.  Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.

Authors:  Jeff Hirst; Harsh B Pathak; Stephen Hyter; Ziyan Y Pessetto; Thuc Ly; Stefan Graw; Devin C Koestler; Adam J Krieg; Katherine F Roby; Andrew K Godwin
Journal:  Cancer Res       Date:  2018-06-11       Impact factor: 12.701

Review 2.  CD133 as a regulator of cancer metastasis through the cancer stem cells.

Authors:  Geou-Yarh Liou
Journal:  Int J Biochem Cell Biol       Date:  2018-11-03       Impact factor: 5.085

3.  Control of AC133/CD133 and impact on human hematopoietic progenitor cells through nucleolin.

Authors:  S Bhatia; S Reister; C Mahotka; R Meisel; A Borkhardt; E Grinstein
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

4.  CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells.

Authors:  Amar Desai; Bryan Webb; Stanton L Gerson
Journal:  Radiother Oncol       Date:  2014-01-16       Impact factor: 6.280

Review 5.  Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity.

Authors:  Jin Qian; Erinn B Rankin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 6.  Unraveling the journey of cancer stem cells from origin to metastasis.

Authors:  Rama Krishna Nimmakayala; Surinder K Batra; Moorthy P Ponnusamy
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-11-09       Impact factor: 10.680

Review 7.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

Review 8.  CD133: to be or not to be, is this the real question?

Authors:  Elena Irollo; Giuseppe Pirozzi
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

9.  Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial.

Authors:  Ola M Ezzatt; Iman M Helmy
Journal:  Clin Oral Investig       Date:  2018-06-16       Impact factor: 3.573

10.  Differential response to intracellular stress in the skin from osteogenesis imperfecta Brtl mice with lethal and non lethal phenotype: a proteomic approach.

Authors:  Laura Bianchi; Assunta Gagliardi; Roberta Gioia; Roberta Besio; Chiara Tani; Claudia Landi; Maria Cipriano; Anna Gimigliano; Antonio Rossi; Joan C Marini; Antonella Forlino; Luca Bini
Journal:  J Proteomics       Date:  2012-02-18       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.